ArticleVaccines2020
mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice.
Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 133 citations in OpenAlex.
- Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therapy.Molecular therapy. Nucleic acids · 2026Review
- An intramuscular prime-intranasal boost strategy for mRNA-LNP vaccine induces mucosal immune response against SARS-CoV-2 in murine model.Journal of translational medicine · 2026Article
- Muscle-targeting LNP vaccines enable potent immune responses against varicella zoster virus.Drug delivery and translational research · 2026Article
- Article
- Intranasal administration of spike-specific mRNA-LNP confers more protection than the intramuscular route against SARS-CoV-2.Iranian journal of basic medical sciences · 2026Article
- Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma.Current issues in molecular biology · 2025Review
- mRNA vaccine based on high-frequency prevalent antigens provides broad protection against influenza B virus.Molecular therapy. Nucleic acids · 2025Article
- Deep generative optimization of mRNA codon sequences for enhanced mRNA translation and therapeutic efficacy.Nature communications · 2025Article
- Review
- Broad-spectrum vaccines against various and evolving viruses: from antigen design to nanoparticle delivery.Journal of virology · 2025Review
- Harnessing the Potential of mRNA Vaccines Against Infectious Diseases.Microbial biotechnology · 2025Review
- Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.Pharmaceutics · 2025Review
- Generation of an inflammatory niche in a hydrogel depot through recruitment of key immune cells improves efficacy of mRNA vaccines.Science advances · 2025Article
- Advances in Therapeutic Cancer Vaccines, Their Obstacles, and Prospects Toward Tumor Immunotherapy.Molecular biotechnology · 2025Review
- Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.Virology journal · 2025Review
- Muco-Penetrating Lipid Nanoparticles Having a Liquid Core for Enhanced Intranasal mRNA Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting Respiratory Viruses: The Efficacy of Intranasal mRNA Vaccination in Generating Protective Mucosal and Systemic Immunity Against Influenza A (H1N1).Influenza and other respiratory viruses · 2025Article
- Developing mRNA Nanomedicines with Advanced Targeting Functions.Nano-micro letters · 2025Review
- UTR-Insight: integrating deep learning for efficient 5' UTR discovery and design.BMC genomics · 2025Article
- A T cell-based ubiquitin-mediated mRNA vaccine provides cross-protection against H1N1 and B influenza viruses in mice.Current research in microbial sciences · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
The design of the mRNA vaccine involves the selection of in vitro transcription (IVT) systems and nonviral delivery vectors. This study aimed to verify the effect of 5' and 3' untranslated region (UTR) sequences on the translation efficiency of mRNA. Three modes of IVT-mRNA systems (IVT-mRNA-n1/n2/n3) with diverse UTRs were constructed, and EGFP (enhanced green fluorescent protein) and HA (hemagglutinin) gene of H3N2 influenza virus were introduced into each of them. The results showed that the mode of 5' and 3' UTRs originating from human β-globulin was better than the mode of UTRs from human α-globulin, and the n3 mode was the best. mEGFP-n3, mH3HA-n3, and mLuciferease-n3 were prepared to compare the effect of cationic lipid nanoparticle (LNP) with that of mannose-conjugated LNP (LNP-Man) on the efficiency of gene delivery. The results showed that the effect of LNP-Man was better than that of LNP both in vitro and in vivo. Choosing appropriate ligands might help in vaccine design. After selecting the IVT-mRNA-n3 system and delivery vectors, mRNA vaccines were constructed against the H1N1 influenza virus, and C57BL/6 mice were immunized through intranasal administration. The results showed that mRNA vaccines could elicit both humoral and cellular immune responses and completely protect mice from the tenfold LD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.